Skip to main content
. 2017 Jun 23;4(2):e000562. doi: 10.1136/openhrt-2016-000562

Table 1.

Patient baseline characteristics and demographics

Normal (n=80) Unobstructed CAD (n=88) Unobstructed (n=168) Obstructive CAD (n=83) p Value
Age 58.6±8.8 63.5±10.3 61.1±9.8 64.3±9.7 0.013
Sex (M:W) 32:48 (40%) 45:43 (51%) 77:91 (46%) 58:25 (70%) <0.001
BMI 30.3±5.4 30.8±5.7 30.4±5.5 30.0±7.0 0.59
Smoking (current) 10 (12%) 14 (16%) 24 (14%) 14 (17%) 0.34
Hypercholesterol 54 (68%) 71 (81%) 125 (74%) 69 (83%) 0.31
HTN 40 (50%) 40 (45%) 90 (54%) 43 (52%) 0.82
DM 12 (15%) 29 (33%) 41 (24%) 16 (19%) 0.19
FHx MI 33 (42%) 47 (53%) 80 (48%) 39 (47%) 0.91
Antiplatelet use 60 (75%) 51 (58%) 111 (66%) 66 (78%) 0.11
 Aspirin 58 34 92 57
 P2Y12 0 6 6 2
 Both 2 11 13 7
Statins 50 (63%) 50 (63%) 109 (65%) 66 (80%) 0.045

All Caucasians but two. Other lowering lipid drugs: four ezetimibe and two fenofibrates.

BMI, body mass index; CAD, coronary artery disease; DM, diabetes mellitus; FHx MI, family history of stroke myocardial infarction; HTN, hypertension; M:W, men:women.